Key Highlights
- The FDA approved pritelivir, an oral drug for persistent herpes simplex sores in certain patients with weakened immune systems.
- Sores healed completely within 28 days in 62.7 percent of patients on pritelivir, versus 34 percent on other treatments.
- The trial enrolled 101 participants and compared pritelivir with doctors’ choice of foscarnet, cidofovir or imiquimod.
- Asahi Kasei earlier estimated a US patient pool of about 15,000 and peak annual sales above $400 million.
Approval for a Hard-to-Treat Group
The US Food and Drug Administration on Friday approved pritelivir, an oral drug for persistent herpes simplex virus sores in certain patients with weakened immune systems who have not responded to available antiviral treatments. Japan’s Asahi Kasei holds the drug through its April Acquisition of German drugmaker Aicuris, which developed it.
The patient groups in the trial program include transplant recipients, people with cancer or autoimmune disorders, and people living with HIV, as shown in company data presented this year.
How the Drug Works
Pritelivir blocks proteins the herpes virus needs to copy its genetic material, stopping it from multiplying. Aicuris describes it as a helicase-primase inhibitor that acts on both herpes simplex virus types 1 and 2.
That mechanism differs from older first-line drugs, which must be activated by a viral enzyme before they can block replication. Mutations that disrupt the activation step cause resistance, and pritelivir works against some infections resistant to those older medicines.
What the Trial Showed
The approval rested on a late-stage trial, known as PRIOH-1, of 101 participants. Sores healed completely within 28 days in 62.7 percent of patients given pritelivir, against 34 percent of those on other treatments. The comparison group received doctors’ choice of intravenous foscarnet, the main approved alternative, or cidofovir and imiquimod, older medicines used off-label.
Company data presented at a European infectious diseases conference this year covered patients who stayed on treatment to 42 days. Complete healing reached 82.4 percent on pritelivir against 42.0 percent on the comparison therapies, and 2.0 percent of pritelivir patients stopped treatment against 20 percent of the others.
Side Effects and Sales Estimates
The most commonly reported side effects in the trial were headache, diarrhea, nausea, reduced appetite, vomiting and dizziness. Asahi Kasei had earlier estimated that about 15,000 US patients with weakened immune systems are candidates for the drug, and put peak annual sales at more than $400 million in the mid-to-late 2030s.
The Path to Approval
Aicuris had received Breakthrough Therapy Designation for pritelivir, submitted its application to the FDA in the first quarter of 2026 and obtained priority review. Priority review sets a shorter target timeline for the FDA’s decision than a standard application, and breakthrough designation is meant to speed the development of drugs for serious conditions.






Please wait processing your request...